TMC207 is a first-in-class anti-TB diarylquinoline (also named R207910 or the 'J' compound) with activity against drug-sensitive and drug-resistant TB. TMC207 inhibits the proton pump of ...

Researchers suggested that BPD-9 could be killing Mycobacterium tuberculosis in a way that is different than that of existing ...

The new compound provides a promising chemical scaffold to develop new potent anti-tuberculosis drugs. M. tuberculosis, the ...

This study aimed to calculate the incidence of AKI due to anti-TB drugs and analyze the outcomes and predictors of renal recovery. Methods: From 2006 to 2010, patients on anti-TB treatment were ...

Whole genome CRISPRi screening identifies druggable vulnerabilities in an isoniazid resistant strain of Mycobacterium ...

Rutgers Health research has uncovered why a relatively new antibiotic for tuberculosis (TB) works against multidrug-resistant strains, potentially inspiring improved treatments and drug development ...

The new compound provides a promising chemical scaffold to develop new potent anti-tuberculosis drugs. M. tuberculosis, the pathogen responsible for tuberculosis (TB), is the leading cause of ...

Researchers have discovered that a protein complex that helps fight cancer cells also slows the growth of tuberculosis – a ...

While traditional treatments involve high doses of oral anti-TB drugs, they often fail to achieve effective concentrations in the cerebrospinal fluid as the BBB limits the medicines from entering ...